External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Inflammatory disease DDW 2025
Roche and Genentech at

DDW 2025

May 03 - May 06
San Diego, USA / Virtual (Hybrid)
ddw.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
07:30 PM
Duration 60mins San Diego, USA
RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis - Findings from the phase IIb TUSCANY-2 trial
Allegretti JR, Yarur A, Feagan B, Danese S, Schreiber S, Peyrin-Biroulet L, Ha C, Kierkus J, Leong RW, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, Bojic D, Lasch K, Schiffman C, Jairath V
Inflammatory Bowel Disease | Inflammatory Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:15 PM
Duration 15mins San Diego
Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis - Results from TUSCANY-2
Jairath V, Allegretti JR, Yarur A, Danese S, Schreiber S, Peyrin-Biroulet L, Kierkus J, Leong RW, Bojic D, Lasch K, Schiffman C, Feagan B
Inflammatory Disease | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.